MarketWatch

IMVARIA Receives 510(k) Clearance for ScreenDx, a First-of-its-Kind Screening Algorithm to Assess for Interstitial Lung Disease

IMVARIA's ScreenDx enhances referral pathways by automatically assessing medical data for interstitial lung findings compatible with interstitial lung disease (ILD) BERKELEY, Calif.--(BUSINESS ...
Medscape

ILD in Rheumatic Diseases: Advice on Screening, Treating, and Monitoring

The prevalence of interstitial lung disease (ILD) across connective tissue disorders (CTDs) and its persistent standing as a leading cause of death in patients with CTDs challenge rheumatologists to ...
The American Journal of Managed Care

Study Highlights Key RA-ILD Risk Factors, Urges Early Screening

RA-ILD significantly increases mortality, with a median survival of less than 3 years post-diagnosis. Key risk factors include male gender, older age, smoking, pulmonary comorbidities, rheumatoid ...
Medscape

Study Homes In On Risk for Interstitial Lung Disease in Patients With Early Rheumatoid Arthritis

Conventional wisdom holds that the longer a patient has rheumatoid arthritis (RA), the greater their risk for interstitial lung disease (ILD), but a recent analysis from a long-term study has provided ...
Business Wire

IMVARIA Receives 510(k) Clearance for ScreenDx, a First-of-its-Kind Screening Algorithm to Assess for Interstitial Lung Disease

BERKELEY, Calif.--(BUSINESS WIRE)--IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced its second FDA authorization, securing 510(k) clearance from ...